The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants.
In times of stress the hypothalamic-pituitary-adrenal (HPA) axis is activated and releases two neurohormones, corticotropin-releasing hormone (Crh) and arginine vasopressin (Avp), to synergistically stimulate the secretion of adrenocorticotropin hormone (ACTH) from the anterior pituitary, culminating in a rise in circulating glucocorticoids. Avp mediates its actions at the Avp V1b receptor (Avpr1b) present on pituitary corticotropes. Dysregulation of the stress response is associated with the pathophysiology of depression and a major treatment involves increasing the availability of monamines at the synaptic cleft. Acute administration of selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) has previously been shown to activate the HPA axis. The present study was undertaken to evaluate the involvement of the Avpr1b in the HPA axis response to acute SC administration of an SSRI (fluoxetine 10mg/kg) and a TCA (desipramine 10mg/kg). We measured plasma ACTH and corticosterone (CORT) levels and neuropeptide mRNA expression in the hypothalamic paraventricular nucleus (PVN) of Avpr1b knockout (KO) mice and wild-type controls. Fluoxetine and desipramine administration significantly attenuated plasma ACTH and CORT levels in male and female Avpr1b KO mice when compared to their wild-type counterparts. Avp, oxytocin (Oxt) and Crh mRNA expression in the PVN did not change in fluoxetine-treated male Avpr1b KO or wild-type mice. In contrast, fluoxetine treatment increased PVN Avp mRNA levels in female Avpr1b wild type but not KO animals. PVN Oxt mRNA levels increased in fluoxetine-treated female mice of both genotypes. The data suggests that the Avpr1b is required to drive the HPA axis response to acute antidepressant treatment and provides further evidence of a sexual dichotomy in the regulation of PVN Avp/Oxt gene expression following antidepressant administration.
Stewart
Lesley Q
LQ
University of Bristol, Whitson Street, Bristol BS1 3NY, UK.
Roper
James A
JA
Young
W Scott
WS
O'Carroll
Anne-Marie
AM
Lolait
Stephen J
SJ
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000704:Analysis of Variance; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000235:genetics / Q000378:metabolism; D003345:Corticosterone / Q000097:blood*; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism; D003891:Desipramine / Q000494:pharmacology; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010121:Oxytocin / Q000235:genetics / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D017483:Receptors, Vasopressin / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D012737:Sex Factors
D000324:Adrenocorticotropic Hormone; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D001127:Arginine Vasopressin; D003345:Corticosterone; D003346:Corticotropin-Releasing Hormone; D003891:Desipramine; D005473:Fluoxetine; D010121:Oxytocin; D012333:RNA, Messenger; D017483:Receptors, Vasopressin; D017367:Selective Serotonin Reuptake Inhibitors